Zeev Rotstein was named Chairman of the Board of ENvue Medical, Inc. As of November 6, 2026, ENvue Medical, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on July 14, 2026, naming 3 appointments (Form 8-K, July 14, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like ENvue Medical, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Zvi Joseph · 8-K, 2026-07-14
- · In / out: In · Person: Zeev Rotstein · Role: Director · 8-K, 2026-07-14
- · In / out: In · Person: Zeev Rotstein · Role: Chairman of the Board · 8-K, 2026-07-14
ENvue Medical, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-07-14. It names 2 people. Every row below is cited to the filing it comes from, and this page adds each new change as ENvue Medical, Inc. files it.
Also on the record for ENvue Medical, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| June 22, 2026 | Stake report, Schedule 13D/A, by Glibert Christian Michael | — | 5%+ stakes | Source |
| April 17, 2026 | Stake report, Schedule 13D/A, by Glibert Christian Michael | 6.5% of the class | 5%+ stakes | Source |
| March 6, 2026 | Stake report, Schedule 13G/A, by BANK OF AMERICA CORP /DE/ | — | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13D, by Glibert Christian Michael | 22% of the class | 5%+ stakes | Source |
| February 6, 2026 | Stake report, Schedule 13G, by BANK OF AMERICA CORP /DE/ | 21.5% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs ENvue Medical, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on ENvue Medical, Inc. and the records around it.
ENvue Medical, Inc. elsewhere on the record
Companies that share a holder
- BANK OF AMERICA CORP /DE/ also filed stake reports on 74 other companies: BlackRock 2037 Municipal Target Term Trust (Nov 2026), TRIMAS CORP (Nov 2026), PIMCO CALIFORNIA MUNICIPAL INCOME FUND (Nov 2026)
Watch ENvue Medical, Inc.
Get an email when ENvue Medical, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on ENvue Medical, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on ENvue Medical, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ENvue Medical, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-07-14 | In | 8-K, 2026-07-14 | |||
| 2026-07-14 | In | Director | 8-K, 2026-07-14 | ||
| 2026-07-14 | In | Chairman of the Board | 8-K, 2026-07-14 |
Who leads ENvue Medical, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chairman of the Board: Zeev Rotstein, appointed (filed 2026-07-14).
- Director: Zeev Rotstein, appointed (filed 2026-07-14).
New leaders reset buying decisions — get the Full Report on ENvue Medical, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at ENvue Medical, Inc., with the record behind each one.
Find candidates like Director at ENvue Medical, Inc.Every change, in the filing's words
Appointed: Zvi Joseph
Mr. Joseph was appointed to serve on the Company's Audit Committee and Nominating and Corporate Governance Committee.
Appointed: Zeev Rotstein, Director
In addition, Zeev Rotstein, M.D., an existing member of the Board, was appointed to Chair of the Nominating and Corporate Governance Committee.
Appointed: Zeev Rotstein, Chairman of the Board
In addition, Prof. Rotstein was appointed to serve as the new Chairman of the Board.
- On July 14, 2026, each of David Johnson and Nino Pionati voluntarily resigned from their respective positions as members of the Board of Directors (the "Board") of ENvue Medical, Inc. (the "Company").
- Johnson and Pionati's resignations did not resign as a result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.
- In addition, on July 14, 2026, the remaining members of the Board appointed each of Zvi Joseph and Lior Buchman as members of the Board to fill the vacancies created by the resignations of Messers.
- Mr. Buchman was appointed to serve on the Company's Audit Committee and Compensation Committee and will serve as the Chairman of the Compensation Committee.
- As remuneration for their service as directors, Messrs. Joseph and Buchman will receive the same fees as the Company's other non-executive directors.
Tools for this story
Each opens in a new tab, filled in for ENvue Medical, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.